Physician profile
Angie E Cain
NPI 1659556892
$3,767.06
in general payments reported to CMS, 2019-2025
30 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $449 · 2023: $515 · 2024: $1,308 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $493.42 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $407.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $393.93 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $392.64 | 2022-2025 | |
| Novo Nordisk INC | $310.84 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $260.58 | 2023-2025 | |
| Amgen INC. | $231.03 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.76 | 2022-2025 | Jardiance |
| Abbott Laboratories | $115.39 | 2022-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $108.50 | 2022-2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $107.97 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $105.07 | 2023-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $99.92 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biohaven Pharmaceutical Holding Company LTD. | $76.97 | 2022 | |
| Daiichi Sankyo INC. | $67.83 | 2022-2025 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $56.84 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.86 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $51.10 | 2024-2025 | Heplisav-B |
| Shield Therapeutics INC | $39.48 | 2024 | |
| Astellas Pharma US INC | $39.16 | 2024-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $33.04 | 2023-2025 | Quviviq, Quviviq |
| Novartis Pharmaceuticals Corporation | $31.72 | 2022 | |
| Phathom Pharmaceuticals, INC. | $31.47 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $24.44 | 2025 | |
| Inari Medical, INC. | $21.84 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cvrx, INC. | $21.70 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $20.88 | 2025 | Gardasil 9, Capvaxive |
| Stryker Corporation | $19.04 | 2025 | Clottriever Bold Catheter |
| Esperion Therapeutics, INC. | $18.55 | 2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $16.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angie Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.